BYS-10

N/A

Report date: 2022/05/31 11:53:09
NME

Base Information

Drug NameBYS-10
Drug Alias NameBYS10
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Solid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Baiyunshan Pharmaceutical Co Ltd Guangzhou Baiyunshan Pharmaceutical General
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou Baiyunshan Pharmaceutical Co Ltd Guangzhou Baiyunshan Pharmaceutical General
Inactive CompaniesN/A
Active IndicationsMedullary thyroid cancer (MTC)Solid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A